Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

fda

86 stories · Page 3 of 4

Drugs & FDA

A $2.7 Million Gene Therapy, Approved Because Patients Needed Less Cornstarch

Ultragenyx's Genglycos won accelerated approval on a surrogate: a 31 percent cut in daily cornstarch. But the disease is low blood sugar, and by the company's own numbers the treated group spent slightly more time below 70 mg/dL, while liver enzymes spiked in 71 percent and every patient needed ster

Nutrition & Food

Thousands of Genes, 20 Volunteers, No Control Group: The Viral Orange Juice Study

The juice came from a citrus-growers' group, the study had no comparison drink, and 'thousands of genes' rests on 20 people, arriving the same summer the FDA loosened what counts as orange juice.

Drugs & FDA

The Screwworm America Eradicated With Sterile Flies Is Back, and This Time Washington Also Reached for an Emergency-Authorized Chemical

Dicyclanil, an Australian sheep-blowfly chemical with mouse liver tumors in its toxicology file, is now cleared for cattle, swine, goats and wildlife under section 564, the same emergency-use power heavily used for pandemic countermeasures.

Drugs & FDA

The FDA's Reviewers Called This Melanoma Data 'Not Interpretable.' Nine Days Later, the Agency Approved the Drug.

Twice the FDA rejected Replimune's engineered-herpes melanoma therapy, its reviewers calling the single-arm trial not interpretable. The design never changed. A 10-3 advisory vote came anyway, and nine days after that memo, the accelerated approval.

Metabolic & Weight

The Peptide Boom Hides One Divide: Human Trials on a Few, Rodent Data and Case Reports on the Rest

Semaglutide and tirzepatide erased up to 22 percent of body weight in trials with thousands of patients. The research-only peptides sold beside them, like BPC-157, have not completed a single published human efficacy trial. A popular 2026 guide lists them as equals.

Infectious Disease

The FDA Put an Emergency Label on a Zoetis Dog Pill for a Screwworm America Erased in 1966 Without a Single Drug

The sterile-fly barrier that kept the flesh-eating screwworm out of America for sixty years gave way, and Washington's answer has been a run of emergency drug authorizations, the newest for a Zoetis dog pill whose maker's own release cites no efficacy data against the parasite.

Autoimmune & Inflammation

The Finest Immune Map of the Sarcoid Lung Explains Why Its Targeted Drugs Keep Failing

National Jewish Health charted more than 150,000 immune cells from sixteen sarcoidosis patients and found a disease with too many moving parts for any single drug to switch off. The targeted therapy that got furthest had already failed Phase 3 and erased 83 percent of its maker's value.

Drugs & FDA

The FDA Approved Moderna's mRNA Flu Shot for Seniors Without Proving It Works in Them

In February the FDA's own vaccine chief refused to even review it. One week later the agency reversed course, and the trial data never changed.

Investigations

RFK Jr. Promised Radical Transparency. His HHS Gutted the Staff Who Release FDA Inspection Reports and CDC Outbreak Data.

The FDA, CDC, and NIH fielded more than 15,000 records requests in 2024. In April 2025 HHS fired the staff who answer them, rehired some FDA workers a month later under legal pressure, and by August 2026 the federal records backlog had only grown.

Investigations

One Irish Plant Releases Both of Sanofi's Pompe Enzymes. In June, the FDA Called Its Drugs 'Adulterated.'

One Irish plant runs the final release for both of Sanofi's lifelong Pompe enzymes. It just failed an FDA inspection on that exact step, and now the company says the fix could take months while patients confirm their next shipments.

Drugs & FDA

The FDA Said No to Moderna's mRNA Flu Shot in February. By August, the Two Men Who Said No Were Gone.

The FDA refused to even review Moderna's mRNA flu shot in February because it was never tested against the enhanced vaccines seniors are steered toward. The two officials who objected are gone, and the agency approved it anyway, for the oldest patients, on a promise to prove it works later.

Drugs & FDA

The FDA Twice Called This Melanoma Trial Uninterpretable. Then It Approved the Drug, at $450,000 a Course.

Federal reviewers rejected Replimune's melanoma therapy twice, faulting a single-arm trial they called not adequate and well-controlled and its results uninterpretable. No new controlled data ever answered them. After a 10-3 advisory vote, the FDA approved it anyway, at $450,000 a course.

Infectious Disease

Mexican Jalapeños Sickened 1,400 Americans in 2008. Eighteen Years Later, a Different Farm and the Same Import Gap Did It Again.

Salmonella Javiana in jalapeños from Sinaloa has sickened 345 people across 27 states. It is the second time in eighteen years that imported Mexican peppers have done this, and the FDA still physically inspects only about 1 to 2 percent of the food crossing the border.

Drugs & FDA

U.S. Special Operators Carried French Freeze-Dried Plasma for 15 Years Before the FDA Licensed an American One

Allied militaries and U.S. commandos have relied on freeze-dried plasma for years. Washington licensed its own version this week, decades after an American doctor first invented the powder.

Drugs & FDA

The FDA Cleared a CRISPR Cure for Two-Year-Olds Whose Own Trial Enrolled No One That Young

Casgevy's pediatric trials enrolled 11 children aged five and up, yet the FDA extended the $2.2 million therapy down to age two, where the conditioning chemo can permanently sterilize a child too young to bank eggs or sperm.

Nutrition & Food

The FDA Revoked Two Petroleum Dyes That Industry Abandoned Before Most Americans Were Born

Orange B was last certified in 1978. Citrus Red No. 2 has painted Florida oranges since 1959. The six petroleum dyes actually in the food supply remain on a voluntary timeline no manufacturer has publicly signed.

Investigations

A Pharma-Funded Nonprofit Is Lobbying the FDA to Kill Seven Peptides It Can't Sell You

The Partnership for Safe Medicines has deep ties to the drug lobby. Now it's urging the FDA to permanently block BPC-157, MOTS-c and five other off-patent peptides that compounding pharmacies sell cheap.

Drugs & FDA

For Years, a Foreign Factory Could Put the Active Ingredient in Your Medicine and Never Tell the FDA

The FDA led with a paperwork convenience for manufacturers. Buried underneath was the admission that it can't always trace where a drug's active ingredient was made, a blind spot Congress had to order it to close.

Investigations

NEJM Retracted the Study That Approved Amgen's Vasculitis Drug. It Had Never Done That in 200 Years.

The FDA says the drug's superiority result came from re-scoring nine patients after the trial was unblinded. It is still on U.S. shelves while Amgen fights the withdrawal.

Drugs & FDA

The FDA Cleared a Sickle-Cell Cure for Two-Year-Olds in 53 Days. It Starts With Chemo That Can Sterilize Them.

Casgevy is a real advance against a brutal disease. It is also a $2.2 million therapy that requires sterilizing chemotherapy, saw a child die in trials, and reached toddlers on a 53-day review Makary's FDA hands out as a favor.

Drugs & FDA

The FDA Office That Vets Gene Therapy Has Run Through Its Entire Top Tier in a Year

The office that decides whether gene therapies reach patients has lost its director, her deputy, and the man brought in to replace them, all inside twelve months.

Drugs & FDA

The FDA's Fix for a $10 Billion Flood of Chinese Vapes Is a Form the Smugglers Will Ignore

Foreign manufacturers ship most of America's vapes and falsify the customs forms to do it. Washington's answer is to ask them to register with the agency they already evade.

Investigations

His Heart Was Pumping at 10 Percent. The Real Question Is Why It Took an Algorithm to Notice.

An AI tool flagged a 45-year-old's hidden heart failure and the story became 'AI beats your doctor.' The case actually documents a missed standard workup, and it dropped the same week as the FDA clearance.

Investigations

The AI Models Just Failed the Clinical Test We Use to Spot Executive Dysfunction

A new PNAS Nexus study put the same Stroop task neuropsychologists use to screen for executive dysfunction in front of GPT-5, Claude Opus, and Gemini. The accuracy collapse arrives months after the FDA quietly loosened oversight of AI clinical decision support.